TransMedics Ebitda from 2010 to 2024

TMDX Stock  USD 87.11  6.50  8.06%   
TransMedics EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -8 M in 2024. During the period from 2010 to 2024, TransMedics EBITDA regression line of annual values had significance of  0.52 and arithmetic mean of (22,121,077). View All Fundamentals
 
EBITDA  
First Reported
2018-03-31
Previous Quarter
17.1 M
Current Value
13 M
Quarterly Volatility
M
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 11.3 M, Selling General Administrative of 125.5 M or Research Development of 22.2 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 19.64. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Ebitda Growth Pattern

Below is the plot of the Ebitda of TransMedics Group over the last few years. It is TransMedics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Pretty Stable
   Ebitda   
       Timeline  

TransMedics Ebitda Regression Statistics

Arithmetic Mean(22,121,077)
Coefficient Of Variation(33.89)
Mean Deviation4,529,221
Median(22,555,000)
Standard Deviation7,496,149
Sample Variance56.2T
Range30.9M
R-Value0.18
Mean Square Error58.6T
R-Squared0.03
Significance0.52
Slope301,836
Total Sum of Squares786.7T

TransMedics Ebitda History

2024-8 M
2023-7.6 M
2022-29 M
2021-38.5 M
2020-23.2 M
2019-28.8 M
2018-19.7 M

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-7.6 M-8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.